CHILL BRANDS GROUP PLC

Regulatory Filings • Dec 16, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8904W

Zoetic International PLC

16 December 2019

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

16 December 2019

Zoetic International plc

("Zoetic" or the "Company")

Settlement of Diversion Debt

Zoetic, the London listed vertically integrated CBD and natural resources company, is pleased to announce the debt owed to the Company by Diversion Technologies LLC ("Diversion") has now been settled in full.

Further to the announcement made on 28 November 2019, Zoetic's purchase of 950,000 ordinary shares from Diversion has now completed and Diversion has also made a further payment to the Company of $44,854.  The combination of these two transactions fully settles the debt owed by Diversion, including taking account of further expenditure incurred by the Company during the current financial year.

Notice of results

Zoetic will be announcing its interim results for the six months ended 30 September 2019 on Monday 23 December 2019.  At the time of its results, the Company will provide a further update on progress at its operations.

**ENDS**

Enquiries

Zoetic International plc                                                                                               +44 (0) 1738 472 029

Nick Tulloch

IFC Advisory Ltd                                                                                                              +44 (0) 20 3934 6630

Tim Metcalfe

Graham Herring

Florence Chandler

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORGGGAWPUPBGQW